Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · ASTAL LABORATORIES LIMITED · 30 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
ASTAL LABORATORIES LIMITED
BSE: 512600
BSE: 512600
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
ASTAL LABORATORIES LIMITED
StateQ4 FY26 filed
Last close · 30 Oct 2026₹62.98
Market cap₹0.3k cr
TTM P/E · P/B · EV/EBITDA— · 0.79 · —
ASTAL LABORATORIES LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 249 |
| EBITDA (ex other income) | 21 |
| margin % | 8.3 |
| Owners' profit | 15 |
| EPS, as reported (₹) | 8.62 |
| ROE % · ROCE % | 4.4 · 5.6 |
| Debt / equity (x) | 0.15 |
| Cash from operations | (18) |
| Capex | (1) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · ASTAL LABORATORIES LIMITED · 30 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 1 quarters
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 134 |
| Profit before tax | 8 |
| Net profit | 8 |
| EPS (₹) | 2.04 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,31,490 | 35.7 | 5.14 | 23.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,60,243 | 89.1 | 15.53 | 67.1 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,57,330 | 74.3 | 8.95 | 39.1 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,27,267 | 116.3 | 23.43 | 70.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,24,151 | 27.7 | 4.20 | 15.9 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,13,351 | 35.1 | 2.96 | 15.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,667 | 32.8 | 3.21 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,931 | 50.9 | 6.28 | 28.6 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 31.1 | 29.7 | 82 of 158 | 48% |
| P/B | 0.8 | 3.0 | 14 of 163 | 92% |
| ROCE | 5.0 | 10.8 | 124 of 183 | 32% |
| ROE | 4.4 | 9.8 | 119 of 166 | 29% |
| Debt / Equity | 0.1 | 0.2 | 82 of 166 | 51% |
| EBITDA margin | 7.7 | 17.5 | 130 of 165 | 21% |
| Market cap | 268 | 801 | 105 of 181 | 42% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · ASTAL LABORATORIES LIMITED · 30 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 14 Oct 2026 · Routine filing of dematerialization certificate under SEBI Reg 74(5) | compliance | minimal | — | — |
| 30 Sept 2026 · 33rd AGM voting results: All 3 resolutions passed with near-unanimous support | board shareholder meetings | low | — | — |
| 30 Sept 2026 · AGM results: all 3 resolutions pass with over 99.99 percent support | board shareholder meetings | medium | — | — |
| 30 Sept 2026 · Trading window closed from Oct 1 until Q2 results announcement | compliance | minimal | — | — |
| 30 Sept 2026 · Board approves Internal, Cost and Secretarial Auditor appointments | management changes | medium | — | — |
| 30 Sept 2026 · Ms. Ambika Kedia appointed as Company Secretary at Astal Laboratories | management changes | low | — | — |
| 29 Sept 2026 · Outcome of 33rd AGM held on September 29, 2026 | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Promoter ACESO Research Labs LLP purchases shares of Astal Laboratories | ownership changes | medium | — | — |
| 9 Sept 2026 · Newspaper publication of 33rd AGM notice submitted to BSE | compliance | minimal | — | — |
| 7 Sept 2026 · 33rd AGM on 29 Sept 2026 and FY26 Annual Report intimation | board shareholder meetings | low | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in